What are the limitations of the mwho cardiac risk?

While the mwho cardiac risk is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the mwho cardiac risk to ensure safe bedside use and optimal diagnostic accuracy.

How does the mwho cardiac risk compare to other Obstetrics scores?

The mwho cardiac risk is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the mwho cardiac risk free to use?

Yes. OpiCalc provides the mwho cardiac risk completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

mWHO Cardiac Risk

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Clinical Uses

Pre-conception counseling for women with structural or functional heart disease.
Directing the frequency of multidisciplinary maternal-fetal and cardiology surveillance during pregnancy.
Determining absolute contraindications to pregnancy.

Hemodynamic Crisis

Pregnancy induces a 50% increase in blood volume and cardiac output. The mWHO scale predicts which diseased hearts will catastrophically decompensate under this unique, 9-month physiologic stress test.

CLINICAL INSIGHT

How it Works

Class I & II (Low to Moderate Risk)

Class I

Class II

Class II-III

Class III & IV (High to Extreme Risk)

Class III

Class IV

CLINICAL INSIGHT

Practical Pearls

Notorious Pitfalls

Pulmonary Arterial Hypertension (PAH) carries a maternal mortality rate of 20-50%. If a Class IV patient presents pregnant, termination is strongly medically advised.
Mechanical valves (Class III) are incredibly difficult to manage. Warfarin is highly teratogenic, but switching to heparin exponentially increases the risk of maternal mechanical valve thrombosis and death. It strictly requires a highly specialized cardio-obstetrics team.
Peri-partum cardiomyopathy is a uniquely unpredictable, often catastrophic heart failure that develops in the last month of pregnancy or first few months postpartum, regardless of prior baseline.

CLINICAL INSIGHT

Next Steps

Management Triggers

Class I: Routine prenatal care with 1-2 cardiology visits.
Class II: Delivery at local hospital is generally safe; cardiology review every trimester.
Class III: Requires delivery at a highly-resourced tertiary care center with cardiothoracic surgery on standby. Bi-monthly cardiology/MFM visits.
Class IV: If patient refuses termination, requires extreme surveillance. Planned early delivery (often via planned C-section in a cardiac OR) with intensive care team.

CLINICAL INSIGHT

Evidence Base

European Society of Cardiology

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.Eur Heart J.2018

CLINICAL INSIGHT

Background

Evolution of Maternal Cardiology

Historically, women with complex congenital heart disease did not survive into childbearing age. Surgical advancements created an entirely new demographic of pregnant women with repaired (but not normal) hearts, necessitating the creation of the mWHO index.

mWHO Cardiac Risk

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Clinical Uses

Pre-conception counseling for women with structural or functional heart disease.
Directing the frequency of multidisciplinary maternal-fetal and cardiology surveillance during pregnancy.
Determining absolute contraindications to pregnancy.

Hemodynamic Crisis

CLINICAL INSIGHT

How it Works

Class I & II (Low to Moderate Risk)

Class I

Class II

Class II-III

Class III & IV (High to Extreme Risk)

Class III

Class IV

CLINICAL INSIGHT

Practical Pearls

Notorious Pitfalls

Pulmonary Arterial Hypertension (PAH) carries a maternal mortality rate of 20-50%. If a Class IV patient presents pregnant, termination is strongly medically advised.
Mechanical valves (Class III) are incredibly difficult to manage. Warfarin is highly teratogenic, but switching to heparin exponentially increases the risk of maternal mechanical valve thrombosis and death. It strictly requires a highly specialized cardio-obstetrics team.
Peri-partum cardiomyopathy is a uniquely unpredictable, often catastrophic heart failure that develops in the last month of pregnancy or first few months postpartum, regardless of prior baseline.

CLINICAL INSIGHT

Next Steps

Management Triggers

Class I: Routine prenatal care with 1-2 cardiology visits.
Class II: Delivery at local hospital is generally safe; cardiology review every trimester.
Class III: Requires delivery at a highly-resourced tertiary care center with cardiothoracic surgery on standby. Bi-monthly cardiology/MFM visits.
Class IV: If patient refuses termination, requires extreme surveillance. Planned early delivery (often via planned C-section in a cardiac OR) with intensive care team.

CLINICAL INSIGHT

Evidence Base

European Society of Cardiology

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.Eur Heart J.2018

CLINICAL INSIGHT